Results 11 to 20 of about 10,647 (219)

Mesenteric extraovarian Sertoli-Leydig cell tumor without DICER1 hotspot mutation: a case report [PDF]

Diagnostic Pathology, 2019
Background Ovarian Sertoli-Leydig cell tumors (SLCTs) with androgenic manifestations harbor DICER1 mutations in 30–60% of cases. Ovarian SLCTs without DICER1 hotspot mutations have been reported to exhibit elderly onset and no androgenic manifestations ...
Mitsumasa Osakabe, Chie Sato, Masamichi Suzuki, Ryo Sugimoto, Yasuko Fujita, Noriyuki Uesugi, Kazuyuki Ishida, Hiroaki Itamochi, Tsukasa Baba, Tamotsu Sugai   +9 more
doaj   +2 more sources

Poorly differentiated, ovarian Sertoli-Leydig cell tumor with heterologous rhabdomyosarcoma and glandular elements: Diagnosis and management of a rare neoplasm [PDF]

Gynecologic Oncology Reports, 2018
Ovarian Sertoli-Leydig cell tumors (SLCT) represent
Charanjeet Singh, Sarfraz Ahmad, Fouad M. Hajjar, Robert W. Holloway   +3 more
doaj   +2 more sources

Histological Analysis of Multiple Unilateral Testicular Tumors in Dogs [PDF]

Life
Testicular tumors are, after skin tumors, the most common neoplasms in male dogs. Among all animals, these tumors occur most frequently within dogs. The etiology remains unclear, although the ectopic (non-scrotal) positioning of the testicles has an ...
Mirosław Kuberka, Przemysław Prządka, Stanisław Dzimira   +2 more
doaj   +2 more sources

Ovarian Sertoli-Leydig cell tumor: A case report

Asian Journal of Surgery, 2023
Guoyan Liu, Weifang Liu, Jinbo Ma, Yueling Tang, Jianyu Ye   +4 more
doaj   +2 more sources

Simultaneous Sertoli Cell-Only Syndrome and Leydig Cell Tumor in a Patient with Azoospermia: A Rare Case Report

Case Reports in Oncology, 2022
Testicular cancers comprise 1–1.5% of entire cancers in men, and sex cord-stromal tumors include 5% of testicular cancers. This study aims to report a simultaneous Sertoli cell-only syndrome and Leydig cell tumor in the same patient.
Rawa Bapir, Rawezh Q. Salih, Karzan M. Salih, Bana Shabur, Abdulwahid M. Salih, Fahmi H. Kakamad, Hiwa O. Abdullah, Fattah H. Fattah, Shvan H. Mohammed   +8 more
doaj   +1 more source

Sertoli Leydig Cell Tumour Initially Misdiagnosed as Polycystic Ovarian Syndrome and Congenital Adrenal Hyperplasia: A Case Report

Journal of Nepal Medical Association, 2020
Sertoli-Leydig cell tumor of the ovary is an unusual neoplasm that belongs to a group of sex cord-stromal tumors of the ovary and accounts for less than 0.5% of all primary ovarian neoplasms.
Pooja Paudyal, Geeta Gurung, Josie Baral, Nisha Kharel   +3 more
doaj   +1 more source

Mixed sex cord–stromal tumor (gynandroblastoma) with malignant morphology involving both ovaries: a case report

Journal of International Medical Research, 2023
Mixed sex cord–stromal tumors, which consist of poorly differentiated Sertoli cells and Leydig cells and juvenile granulosa cell tumor tissue, are extremely rare.
Bayan Maraqa, Maxim Al-Ashhab, Nazmi Kamal, Maher Sughayer, Fareed Barakat   +4 more
doaj   +1 more source

Poorly differentiated ovarian sertoli–Leydig cell tumor in a 12-month-old girl

Journal of Indian Association of Pediatric Surgeons, 2020
Kriti Chauhan, Jyotsna Singh
doaj   +2 more sources

Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries. [PDF]

Gynecol Oncol
Nelson AT, Harris AK, Watson D, Kamihara J, Chen KS, Stall JN, Devins KM, Young RH, Olson DR, Mallinger PHR, Mitchell SG, Hoffman LM, Halliday G, Suleymanova AM, Glade Bender JL, Messinger YH, Herzog CE, Field AL, Frazier AL, Stewart DR, Dehner LP, Hill DA, Billmire DF, Schneider DT, Schultz KAP.   +24 more
europepmc   +2 more sources

Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell turnours [PDF]

, 2007
Background: Sertoli-Leyclig cell tumours of the ovary account for only 0.2% of malignant ovarian tumours. Two-thirds of all patients become apparent due to the tumour's hormone production. Methods: A 41-year-old patient (gravida 4, para 4) presented with
Campisi P, Ching B, Clinton CW, Dhont M, Emons G, Gershenson DM, O'Hern TM, Prinz RA, Schwartz PE, Tampakoudis P, Young RH, Young RH, Zaloudek C   +12 more
core   +2 more sources